Response to recombinant human growth hormone (r-hGH) in the first year of therapy has been associated with singlenucleotide polymorphisms (SNPs) in children with GH deficiency (GHD). Associated SNPs were screened for regulatory function using a combination of in silico techniques. Four SNPs in regulatory sequences were selected for the analysis of in vitro transcriptional activity (TA). There was an additive effect of the alleles in the four genes associated with good growth response. For rs3110697 within IGFBP3, rs1045992 in CYP19A1 and rs2888586 in SOS1, the variant associated with better growth response showed higher TA with r-hGH treatment. For rs1024531 in GRB10, a negative regulator of IGF-I signalling and growth, the variant associated with better growth response had a significantly lower TA on r-hGH stimulation. These results indicate that specific SNP variants have effects on TA that provide a rationale for their clinical impact on growth response to r-hGH therapy.
Introduction
Children with growth hormone (GH) deficiency (GHD) have significant inter-individual variation in response to recombinant human GH (r-hGH). Some of this variation can be ascribed to clinical or biochemical factors (e.g. age, GH peak response, weight and r-hGH dose at the start of treatment) identified in growth prediction models. These explain~60% of r-hGH responsiveness over the first year of therapy [1] [2] [3] . However, as human growth and response to r-hGH result from an interaction of both genetic and nongenetic factors, the identification of genetic markers in addition to the auxological/biochemical predictors could improve the precision and accuracy of growth prediction [4] [5] [6] .
To date, hundreds of genetic variants associated with adult height (AH) and human growth have been identified [7] [8] [9] . A number of pharmacogenomic studies have been undertaken to study genotype-phenotype correlation [10] [11] [12] [13] [14] [15] [16] [17] . The GH receptor (GHR) gene lacking exon 3 (d3-GHR) has been the most extensively investigated; its carriage was shown to influence both growth response to rhGH [1, 2] and GH signal transduction using in vitro transfection experiments [10] . Subsequent studies reported variable results, with some confirming the role of the d3 allele in growth response and others showing no effect [18, 19] . A meta-analysis conducted on 12 studies confirmed the heterogeneity of results with an overall modest effect of d3-GHR on increased growth response [20] . More recently, response to r-hGH has been shown to depend on an interaction between GHD severity and d3-GHR carriage [21] . Despite the heterogeneity of results, these studies have introduced the important concept that common variations in GH/insulin-like growth factor (IGF) axis genes may play a role in predicting response to r-hGH therapy. Moreover, a gene-environment interaction has been shown to play an important role in determining growth response in GHD children [6] .
Further pharmacogenomic studies have identified, in a number of growth disorders, novel polymorphisms (singlenucleotide polymorphisms (SNPs)) associated with GH response and located within genes involved in growth pathways, including IGFBP3 [22] and SOCS2 [23] , or involved in metabolic processes, such as the leptin receptor gene [24] . To address this issue, the PREDICT study (NCT00699855; Merck Serono S.A.-Geneva, Study 28614) was launched to explore prospectively the effect of these genes on responses to r-hGH in treatment-naive prepubertal children with GHD and Turner syndrome (TS) [25, 26] . The carriage of SNPs in 11 genes in GHD and 10 in TS, with two overlapping between conditions, were significantly associated with first-year growth response [25] . A validation study supported the association of four of these genetic markers with first-year response to r-hGH treatment in GHD and TS children after controlling for clinical/auxological covariates, although the contribution of these SNPs in a prediction model of first-year response was not deemed sufficient for routine clinical use [27] .
Demonstrating that the SNPs in regulatory regions of DNA associated with growth response have functional consequences is important to provide a rationale for their clinical impact. The aims of this study were to (1) to identify SNPs associated with response to r-hGH therapy in GHD children who were likely to have a functional effect on transcription and (2) assess the impact of a number of these polymorphisms on transcriptional activity (TA). We adopted a two-step approach: first, polymorphisms were selected using in silico methods and by literature search to assess their potential effect on transcription [28] ; second, the chosen polymorphisms were linked to clinical phenotype by carriage of SNP variants, their additive contribution to growth response was assessed and their TA was tested in vitro (Fig. 1 ).
Methods

Selection of polymorphisms
The selection of the genetic markers was performed, calculating a total score of 8 using two approaches: in silico study (graded 0-5) and literature search (graded 0-3) [scoring system described below]. Only the SNPs with a total score of 3 or above were selected. Ten polymorphisms linked to seven different genes were analysed; all had been associated with a good growth response on r-hGH (within the upper quartile of growth in the first year [cm]) in a continuous analysis in the PREDICT study [25] . These included the gene coding for the major GH-dependent carrier of IGF-I in the circulation, IGFBP3; signalling molecules GRB10 and SOS1 (mitogen-activated protein kinase pathway); the growth factor TGF-α; the phosphatase INPPL1; the tumour-suppressor TP53; and CYP19A1, a P450 cytochrome enzyme with aromatase activity (Table 1) .
In silico analysis
An in silico database search was undertaken to identify the location of the SNP (and its proximity to regulatory elements within the gene-promoters and their transcription binding sites and enhancers or repressors) using the UCSC Genome Browser (https://www.genome.ucsc.edu/) with the human hg18 build. These data were derived from many different cell lines in which transcription factors and their binding sites responsible for modulating gene transcription, as identified by chromatin immunoprecipitation-sequencing, are listed in the ENCODE (Encyclopaedia of DNA Elements) database (http://genome.ucsc.edu/ENCODE/) [29] . Data were also available on the number of cell lines in which TA is predicted to be affected by the region in which the SNP is located, using markers of chromatin state (http:// genome.ucsc.edu/cgibin/hgTrackUi?hgsid = 224899637&g = wgEncodeBroadHmm) [30] .
Five markers of TA were considered: (1) proximity to transcription factor binding sites; (2) sites of DNAse hypersensitivity-DNA-hypersensitive sites are considered to be accessible to transcription factors; (3) chromatin state segmentation using nine different cell lines; (4) nucleosome occupancy-dynamic changes in nucleosome occupancy are known to be associated with the presence of transcriptional and chromatin regulators [31] ; and (5) mammalian conservation [29, 30, 32] . The presence/absence of each marker was calculated with a score of 1 and 0, respectively. A maximum score of 5 was indicative of a polymorphism predicted to have high TA, whereas a score of 0 predicted no TA. Fig. 1 Algorithm on the methods used for the assessment of the functional impact of polymorphisms. Two steps were undertaken: step (1) in silico modelling and literature search to select a number of polymorphisms; step (2) the chosen polymorphisms were analysed by genotype in terms of growth response and tested in in vitro cell models Polymorph- 
The table shows in order:
(1) The gene in which the SNP is located, the gene ID and the RefSeqGene (2) Position: identifies the location of the SNP in the genome (hg18 build). Most polymorphisms were located within intronic regions of the gene. 
Literature search
The literature search assessed the strength of the evidence that the polymorphism was associated with clinical parameters, including AH and growth response to r-hGH. Genes related to AH in genome-wide association studies (GWAS) were assessed by "GWAS Central" (available on http://www.gwascentral.org/) [33] , using the negative logarithmic p-value (−log p). A score of 1 was given for a −log p ≥ 1.0 which was considered as a tentative association with the trait, with a score of 0 given for a −log p < 1.0. The polymorphisms were further analysed in relation to the association with growth response to r-hGH, as previously reported in the PREDICT study [25] . The unadjusted p-value was evaluated. A p-value ≤ 0.001 for carriage of a SNP variant, considered as strongly associated with response to r-hGH, was assigned a score of 2 with a score of 0 given if the p-value > 0.001. A maximum score of 3 was indicative of a polymorphism predicted to have clinical relevance, being associated with AH and growth response to r-hGH.
Analysis of growth response for the selected polymorphisms
Patients' data were used from the previously published PREDICT long-term follow-up (LTFU) prospective study [25] . Data linking growth response after 1 year of r-hGH therapy to carriage of associated SNPs was presented as previously published in the per protocol set of GHD children (n = 115) [25] . These data were supported by linking patient auxology to carriage of SNPs in the intention to treat cohort (n = 118). Children were recruited from 14 countries [25] .
All children were naive to r-hGH therapy and prepubertal at the start of treatment. The diagnosis of GHD was based on two different stimulation tests with a peak GH < 10 μg/l [34] . The median peak GH value was 4.1 μg/l. Patients were selected for r-hGH treatment by their local units and received r-hGH at an average dose of 35 μg/kg/day.
Subjects were excluded with acquired GHD due to central nervous system disorders, such as tumour, trauma, infection, infiltration, irradiation and cranial surgery. Other hormone deficiencies (cortisol and thyroxine), if present, were appropriately treated.
Analysis was conducted using growth response defined as: (1) annualized height velocity (HV, cm per year) at the first-year visit (12 ± 3 months of first-year treatment anniversary) and (2) 1-month change in circulating IGF-I levels, as previously reported [26] .
This study was conducted in compliance with ethical principles based on the Declaration of Helsinki, the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice and all applicable regulatory requirements. Written informed consent was obtained from all parents and oral consent from all children.
Analysis of TA
For the chosen polymorphisms, TA was assessed using reporter constructs. Each SNP was centrally located within a 500 bp fragment of synthesized promoter sequence (Gene Art, ThermoFisher, UK) and inserted into the pSEAP2 vector (Clontech Laboratories). The vector contained secreted alkaline phosphatase (SEAP) as a reporter gene, using restriction enzyme (MluI 5' and XhoI 3') mediated heterologous directional cloning and antibiotic selection (Ampicillin). The reporter constructs were transiently transfected into the human MCF-7 cell line (from early passage stocks tested mycoplasma free), known to be GH responsive [35, 36] . Transfections were performed with Effectene® Transfection Reagent (Qiagen), as per the protocol. The experiments were performed using 24-well plate and seeding the day before of the transfections with 2-8 × 10 4 cells. Genotypes were mimicked using a 1:1 stoichiometric mix of the relevant reporter gene constructs.
TA of each construct was evaluated by relative SEAP induction at baseline and after 24 h of GH stimulation (range: 2 and 20 ng/ml) using a luminometer and Ready-ToGlow Dual Secreted Reporter Vector Kit (Clontech) [10, 37] . This assay system measures SEAP as the reporter of TA and luciferase on the plasmid backbone as cotransfection control. The experiments were performed using empty vectors as controls. Three independent sets of experiments were performed at baseline and after GH stimulation, each experiment was performed in triplicate.
The experiments were performed in triplicate using 24-well plates with cell seeding the day before transfection at a density of 2-8 × 10 4 cells in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum (Invitrogen, Paisley, UK). Cells were cultured in stable conditions at 37°C, 5% CO 2 in 75 cm 2 cell culture flasks.
Statistical analysis
All data were expressed as mean ± standard deviation (SD). Differences in continuous variables were examined for unpaired samples by Kruskal Wallis test due to the ranked nature of the data and the small sample size. Differences in categorical variables were assessed by χ 2 test. Unpaired Student's t-tests were used to compare the results of transfection with different genotypes for each SNP. A p-value <0.05 was considered statistically significant.
Correlation and regression analysis to link the additive effect of SNPs to growth response was undertaken using a scoring system for carriage. Carriage of SNP variants associated with growth response after 1 year of r-hGH therapy was defined as previously published [25] . For allele carriage, the best growth response was assigned a score of 1 and the poorer response was scored 0. The scores for carriage were added across the four SNPs and the total scores were generated for each individual patient. These data were then plotted against growth response after 1 year of r-hGH therapy as a scatter plot and a least squares regression line was fitted. Pearson's product-moment correlation was then performed to determine confidence in the findings.
Statistical analysis was performed using R [38] and the Statistical Package for Social Science (SPSS) program, version 20.0 software for Windows (SPSS, Chicago, IL, USA).
Results
Selection of polymorphisms to study in vitro
Four polymorphisms in four different genes were selected as they were predicted in silico to be functional and more strongly associated with clinical outcome, with a total score of 3 or above. These included rs3110697 (A/G) within IGFBP3, rs1024531 (A/G) within GRB10, rs10459592 (G/ T) within CYP19A1 and rs2888586 (C/T) within SOS1. The polymorphisms within TGF-a, INPPL1 and TP53 were not selected as they showed lower prediction of TA and a weaker relationship to growth response ( Table 2) .
The polymorphism rs1024531 (GRB10) was predicted to have weak TA; however, it was located within 100 bp of the binding site for REST (RE1-Silencing Transcription Factor). This SNP was also associated with better growth response to r-hGH, defined by first-year HV in cm/year with the lowest p-value (<0.001) [25] . All the other polymorphisms within GRB10 were predicted to have weak TA and to be variably associated with clinical outcomes. However, the rs1024531 polymorphism was chosen for its highest score based on prediction in silico and on literature searches (5/8 vs 4/8 and 3/8 for rs12536500 and rs933360, respectively).
The polymorphisms rs3110697 (IGFBP3) and rs10459592 (CYP19A1) were situated in a genomic region of high DNase activity and in proximity to transcription factor-binding sites. Moreover, they showed a possible association with AH as indicated by GWAS [33] . Specifically, rs3110697 IGFBP3 was located 50 bp upstream of the EGR-1 (early growth response 1) binding site and 100 bp downstream of a STAT3 (signal transducer and activator of transcription 3) binding site [30] . Multiple transcription factors bind to the DNA site containing rs10459592 including c-FOS, JunD, c-JUN, FOSL2 and BATF, all components of the JUN/FOS/ATF complex [30] .
The polymorphism rs2888586 in SOS1 fulfilled three out of the five markers of TA and was predicted to be weakly transcriptionally active in almost all cell lines analysed (eight out of nine). Moreover, it was located in a genomic region with moderate nucleosome occupancy and with mammalian conservation.
The proximity of the SNPs to control elements and the predicted TA of the region in which the SNP was located is shown in Table 2 .
Analysis of growth response for the selected polymorphisms
Clinical and biochemical variables were analysed by carriage for the four selected polymorphisms [rs3110697 (A/ G), rs1024531 (A/G), rs10459592 (G/T) and rs2888586 (C/ T)], carriage of SNP variants were defined as previously reported [25] . These included parameters at baseline (age, gender, height standard deviation score (SDS) and peak GH concentration in response to stimulation testing) and markers of response to r-hGH [HV after the first year of r-hGH therapy [cm] (as previously reported) and 1-month change in circulating IGF-I levels] [26] (Table 3) .
When polymorphisms were divided by carriage, there were no significant differences in the parameters at baseline [age, gender, height SDS and GH peak (all p > 0.05)], with the exception of rs10459592 in CYP19A which had a significantly higher GH peak associated with carriage of T compared to the GG genotype. Significant differences by carriage for first-year HV were presented as previously reported [25] (in cm, p < 0.05) ( Table 3 ).
The additive effect of associated SNPs in response to r-hGH
Scores representing the number of growth-promoting variants of the four SNPs studied were derived for each GHD patient. Carriage of multiple growth-promoting SNPs was correlated with HV after the first year of r-hGH treatment (p = 6.2 × 10 −9 , r = 0.50 [95% confidence interval:
0.36-0.63]) (Fig. 2) .
Analysis of TA of the selected SNPs
We investigated in vitro whether a given genotype within the rs3110697, rs1024531, rs10459592 and rs2888586 polymorphisms affected TA after GH stimulation. We transiently co-transfected MCF-7 cells, known to be GH responsive [33, 35, 39] , using the pSEAP2-Control Vector reporter gene plasmid with vectors expressing either the Table 2 In silico modelling data of the single-nucleotide polymorphisms previously associated with growth response Nucleosome occupancy Analysis was performed on the described tracks below within the UCSC genome browser using the human hg18 build [41] The table shows in silico data, in order:
(1) ENCODE Transcription Factor ChIP Seq, identifies the proximity to transcription factor ChIP-seq findings listed in the ENCODE database [32] . The presence or absence of transcription factors was identified with a score of 1 or 0, respectively (2) DNAse Clusters, identifies sites of DNAse hypersensitivity. This is identified by "Items in clusters" (0-148) and "Cluster ccore" (100-1000). The presence of a DNAse cluster is detected when items in clusters is > 1 and Cluster score is >100. The presence or absence of DNAse hypersensitivity was identified with a score of 1 or 0, respectively (3) Chromatin state segmentation (CSS), identified in 9 cell lines. Above is presented the CSS in the majority of cell lines.
H heterochromatin, LS low signal, WT weakly transcribed, R repressed,
WE weak enhancer, TT transcriptional transition, E enhancer, WE weak enhancer. The presence or absence of WT or TE in the majority of cell lines was identified with a score of 1 or 0, respectively (4) Nucleosome occupancy, this is identified via the signals within K562 and GM12878 cell lines. It has a score of 0 to 8. L: low occupancy (<2); M: moderate occupancy (2-6). H: high occupancy (>8). The score of 0 was given for low occupancy, the score of 1 for moderate to high occupancy in at least one cell line (5) Mammalian conservation, it has a score of 0-4. Not conservative (0); Conservative (1-2); Highly Conservative (3-4). The score of 0 was given for not conservative region, the score of 1 for conservative or highly conservative regions (6) Adult height GWAS, a score of 1 was given for a −log p ≥ 1.0, which was considered as a tentative association with the trait, with a score of 0 given for a −log p < 1.0 (7) PREDICT study, a p-value ≤ 0.001 for carriage of a SNP variant, considered as strongly associated with response to r-hGH, was assigned a score of 2 with a score of 0 given if p-value > 0.001 P-values in bold and underlined scores indicate where they have met the defined criteria
The in vitro functional analysis of single-nucleotide polymorphisms associated with growth hormone (GH)… Table 3 Main clinical and biochemical characteristics of children with GHD by carriage of the polymorphisms rs1024531 in genotype associated with the highest or the lowest HV (Fig. 3) . When the cells were exposed to GH concentrations of 2 and 20 ng/ml, the genotype associated with better growth response induced higher transcription of SEAP at both GH concentrations (p < 0.05). This was observed for the polymorphisms rs3110697 (IGFBP3, genotype GG), rs10459592 (CYP19A1, genotype GG) and rs2888586 (SOS1, genotype TT) (Fig. 3b-d) .
For the SNP rs1024531 within GRB10, the genotype associated with better growth (AA) was associated with significantly lower SEAP induction (p < 0.05) at 2 and 20 ng/ml (Fig. 3a) .
Of note, higher GH concentrations (20 ng/ml) did not further increase SEAP induction for any of the SNPs tested. This might be attributed to a partial response at higher doses due to a limited number of cell surface GHRs. Moreover, the tissue culture flask represents an artificial system in vitro, in which cellular response may reach saturation at GH concentrations much lower than those used in vivo for therapy (Fig. 3) .
Discussion
In this study, we investigated in vitro whether polymorphisms known to be associated with clinical responses to rhGH therapy [25] could affect TA. To achieve this aim, we identified four SNPs using a combination of in silico and literature-based findings that were likely to have an effect on the TA of their associated gene. We developed a model to test TA using a GH-responsive cell line transfected with a construct consisting of the regulatory region of interest containing the SNP variants upstream of a reporter gene. This model identified gene-dependent patterns of TA, providing a platform to test the functional mechanisms that underlie clinical and genetic observations from PREDICT and other GH pharmacogenomic studies.
The GHD patients potentially carried more than one growth response-associated allele from the four SNPs studied. An additive association of these SNPs with growth response was suggested by correlation with both carriage and genotype. This observation was consistent with the existence of a polygenic component to responsiveness to rhGH [9] .
For all the SNPs situated in genes known to promote somatic growth [25] (rs3110697 within IGFBP3, rs2888586 within SOS1 and rs10459592 within CYP19A1), we have linked the carriage of variants previously associated with better growth response [25] with higher TA on GH stimulation. These SNPs were also found to be located in genomic regions near to transcriptional regulators involved in cell growth and response to GH, including STAT3. On the converse, for the SNP rs1024531 within GRB10, the carriage of the variant associated with better growth response was associated with lower TA after GH stimulation. Interestingly, GRB10 is a negative regulator of growth and of signalling through the IGF-I receptor [40] . Specifically, the transfection modelling the genotype AA had reduced TA after GH stimulation, consistent with better growth on GH in GHD children [40] . Importantly, the analysis was conducted using GH stimulation between 2 and 20 ng/ml-a range of GH concentrations similar to physiological serum levels, supporting the in vivo relevance of these findings. SNPs that scored poorly on selection by in silico analysis and literature search were not analysed for TA. All the polymorphisms tested had a higher TA compared to transfection controls.
In this study, we have compared the in vitro bioactivity of different alleles in genes related to GH response. These findings are in alignment with Dos Santos et al. [10] whose method to assess genotype was the transfection of Fig. 2 The additive effect of growth response-associated SNPs. Scatter plots of genetic score against growth response with a least squares regression line. Carriage of SNP variants associated with growth response after 1 year of r-hGH therapy in GHD patients (n = 115) as previously published [25] . For carriage of SNPs, the best growth response was assigned a score of 1 and the group associated with poorer response was scored 0. The scores were added over the four SNPs for each individual patient equivalent stoichiometric ratios of SNP variants. This approach gives an indication of what would occur with a codominant effect but cannot account for chromatin-mediated control of variant expression as would be found in dominant or recessive genetic associations. The associations with growth response previously reported were for carriage of all SNPs along with genotype for GRB10 (rs1024531) and IGFBP3 (rs3110697) [25] . Here, however, TA analysis demonstrates clear effects of each allele in alignment with the growth response linked to SNP variant carriage [25] .
A validation study of the SNPs associated with growth response to r-hGH after 1 year of therapy identified a number of genes common to both the validation and LTFU studies. The impact of the SNPs on growth varied between the studies, at least in part due to differences in the study cohorts [27] . However, by adjusting for co-variant phenotype, an additional weight of evidence was provided that these SNPs do have a role to play in growth response. When GHD severity, as measured by response in two stimulation tests, was used as a covariate, the rs2888586 SNP within SOS1 was found to be associated with change in height (cm) by regression analysis. Additionally, the rs1024531 SNP within GRB10 was shown to be predictive of growth response in severe GHD patients using random forest analysis, while the rs10459592 SNP within CYP19A1 and the rs3110697 SNP within IGFBP3 were also shown to be associated with growth response although the influence of genotype was inconsistent between studies. The association of the CYP19A1 rs10459592 SNP with GH peak, as a marker of GH severity, found in this current study was not seen in the validation study [21] . The demonstration provided here of GH-dependent TA associated with all four SNPs gives additional support for their relevance in mediating differential response to r-hGH therapy in GHD patients.
This study provides a reliable system for studying whether clinically relevant polymorphisms have also a functional correlate and it can be used as a model for further Fig. 3 Transcriptional activity assessed using alkaline phosphatase reporter for four SNPs associated with response to GH therapy. Higher transcriptional activity across all concentrations of GH is seen for the genotype associated with better growth response for all SNPs assessed except GRB10, where lower transcriptional activity was seen with higher growth. Data presented as fold change of secreted alkaline phosphatase (SEAP) induction over empty vector control at 2 ng/ml and 20 ng/ml concentrations of GH. Genotypes were modelled by the transfection of equivalent stoichiometric ratios of variants. A) rs1024531 GRB10, B) rs3110697 IGFBP3, C) rs10459592 CYP19A1, D) rs2888586 SOS1. studies to test new regulatory polymorphisms that may be identified. The strength of this report is to have shown that, in response to a given dose of exogenous GH, individual differences in carriage of these polymorphisms have an effect on the TA of their associated genes linked to clinically relevant changes in GHD patient growth rate. This may help in contributing to the progressive switch in GH prescription from 'fixed dosage' to a more personalized adjustment of dose tailored on the genetic constitution of each child with GHD.
